180 related articles for article (PubMed ID: 26758618)
1. Two new prenylflavonoids from Epimedii Herba and their inhibitory effects on advanced glycation end-products.
Nakashima K; Miyashita H; Yoshimitsu H; Fujiwara Y; Nagai R; Ikeda T
J Nat Med; 2016 Apr; 70(2):290-5. PubMed ID: 26758618
[TBL] [Abstract][Full Text] [Related]
2. Prenylflavonoids isolated from
Nakashima K; Miyashita H; Yoshimitsu H; Fujiwara Y; Nagai R; Ikeda T
Front Chem; 2024; 12():1407934. PubMed ID: 38882216
[No Abstract] [Full Text] [Related]
3. Eucommia ulmoides extracts prevent the formation of advanced glycation end products.
Sugawa H; Ohno R; Shirakawa J; Nakajima A; Kanagawa A; Hirata T; Ikeda T; Moroishi N; Nagai M; Nagai R
Food Funct; 2016 Jun; 7(6):2566-73. PubMed ID: 27080730
[TBL] [Abstract][Full Text] [Related]
4. Astragalosides isolated from the root of astragalus radix inhibit the formation of advanced glycation end products.
Motomura K; Fujiwara Y; Kiyota N; Tsurushima K; Takeya M; Nohara T; Nagai R; Ikeda T
J Agric Food Chem; 2009 Sep; 57(17):7666-72. PubMed ID: 19681610
[TBL] [Abstract][Full Text] [Related]
5. Drosera tokaiensis extract containing multiple phenolic compounds inhibits the formation of advanced glycation end-products.
Tominaga Y; Sugawa H; Hirabayashi K; Ikeda T; Hoshi Y; Nagai R
Arch Biochem Biophys; 2020 Oct; 693():108586. PubMed ID: 32941804
[TBL] [Abstract][Full Text] [Related]
6.
Kinoshita S; Mera K; Ichikawa H; Shimasaki S; Nagai M; Taga Y; Iijima K; Hattori S; Fujiwara Y; Shirakawa JI; Nagai R
Oxid Med Cell Longev; 2019; 2019():9073451. PubMed ID: 31583049
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of AGEs formation by natural products.
Nagai R; Shirakawa J; Ohno R; Moroishi N; Nagai M
Amino Acids; 2014 Feb; 46(2):261-6. PubMed ID: 23504149
[TBL] [Abstract][Full Text] [Related]
8. Amount of N(omega)-(Carboxymethyl)arginine generated in collagen and bovine serum albumin during glycation reactions is significantly different.
Iijima K; Fujimoto D; Irie S
Connect Tissue Res; 2007; 48(5):271-6. PubMed ID: 17882703
[TBL] [Abstract][Full Text] [Related]
9. Effects of the combined Herba Epimedii and Fructus Ligustri Lucidi on bone turnover and TGF-β1/Smads pathway in GIOP rats.
Yang Y; Nian H; Tang X; Wang X; Liu R
J Ethnopharmacol; 2017 Apr; 201():91-99. PubMed ID: 28254481
[TBL] [Abstract][Full Text] [Related]
10. Some natural compounds enhance N epsilon-(carboxymethyl)lysine formation.
Fujiwara Y; Kiyota N; Motomura K; Mera K; Takeya M; Ikeda T; Nagai R
Ann N Y Acad Sci; 2008 Apr; 1126():152-4. PubMed ID: 18079486
[TBL] [Abstract][Full Text] [Related]
11.
Kim JY; Shim SH
Nutrients; 2019 May; 11(5):. PubMed ID: 31109081
[TBL] [Abstract][Full Text] [Related]
12. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
[TBL] [Abstract][Full Text] [Related]
13. Prenylated Flavonoid Glycosides with PCSK9 mRNA Expression Inhibitory Activity from the Aerial Parts of
Kim E; Kim YM; Ahn J; Chae HS; Chin YW; Kim J
Molecules; 2021 Jun; 26(12):. PubMed ID: 34208231
[TBL] [Abstract][Full Text] [Related]
14. Systematic considerations for a multicomponent pharmacokinetic study of Epimedii wushanensis herba: From method establishment to pharmacokinetic marker selection.
Wang C; Wu C; Zhang J; Jin Y
Phytomedicine; 2015 Apr; 22(4):487-97. PubMed ID: 25925971
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of advanced glycation by flavonoids. A nutritional implication for preventing diabetes complications?].
Urios P; Grigorova-Borsos AM; Peyroux J; Sternberg M
J Soc Biol; 2007; 201(2):189-98. PubMed ID: 17978753
[TBL] [Abstract][Full Text] [Related]
16. Synergistic inhibitory effect of Icariside II with Icaritin from Herba Epimedii on pre-osteoclastic RAW264.7 cell growth.
Liu YQ; Yang QX; Cheng MC; Xiao HB
Phytomedicine; 2014 Oct; 21(12):1633-7. PubMed ID: 25442270
[TBL] [Abstract][Full Text] [Related]
17. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
[TBL] [Abstract][Full Text] [Related]
18. Chemical Constituents, Quality Control, and Bioactivity of Epimedii Folium (Yinyanghuo).
Chen XJ; Tang ZH; Li XW; Xie CX; Lu JJ; Wang YT
Am J Chin Med; 2015; 43(5):783-834. PubMed ID: 26243581
[TBL] [Abstract][Full Text] [Related]
19. Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains.
Kimura T; Takamatsu J; Miyata T; Miyakawa T; Horiuchi S
Pathol Int; 1998 Aug; 48(8):575-9. PubMed ID: 9736403
[TBL] [Abstract][Full Text] [Related]
20. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation.
Anderson MM; Heinecke JW
Diabetes; 2003 Aug; 52(8):2137-43. PubMed ID: 12882933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
